Mylan: Brand/Generic Distinction Disintegration Is Necessary
This article was originally published in The Pink Sheet Daily
Executive Summary
Consolidation in the generic industry is good and necessary, Mylan CEO Heather Bresch said during a recent investor presentation. Mylan is well-positioned in the changing market, she said, thanks to business development such as its biosimilars agreements with Biocon and its Japan collaboration with Pfizer.
You may also be interested in...
Mylan And India’s Biocon Team Up To Develop Insulin Biosimilars Of Sanofi, Lilly, Novo Nordisk Products
Less than a year after Pfizer broke out of a deal with Biocon, the company announced it is linking up with Mylan to make biosimilars of insulin products made by Sanofi, Lilly and Novo Nordisk.
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.
Mylan Breathes Life Into Its Specialty Pharma Unit
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.